The Combined Use of Transmyocardial Laser Revascularisation and Intramyocardial Injection of Bone-Marrow Derived Stem Cells in Patients with End-Stage Coronary Artery Disease: One Year Follow-Up
There are a growing number of patients with end-stage coronary artery disease (CAD) and refractory angina. Angiogenesis may be induced by intramyocardial injection of autologous bone marrow stem cells, intensified by inflammationaround channels performed by laser.
Coronary Artery Bypass Grafting after Aprotinin: Are We Doing Better?
Accordingly, the usage of aprotinin should be reconsidered for treatment among cohorts of low-risk cardiac patients.
Pharmacologic Tools to Reduce Bleeding in Surgery
Strategies to reduce blood loss and the need for transfusions in surgery include enhancement of coagulation, inhibition of fibrinolysis, and an improved decision algorithm for transfusion based on bedside monitoring of global hemostasis.
The Mechanisms of Cell Therapy for Clinical Investigations: An Urgent Need for Large-Animal Models
Evidence from experiments performed in animal models and from early-stage clinical trials demonstrate that the contractile performance of hearts with severe ischemic injury can be improved by transplanting a variety of cell types into the injured heart.
Mini-Extracorporeal Circulation Minimizes Coagulation Abnormalities and Ameliorates Pulmonary Outcome in Coronary Artery Bypass Grafting Surgery
Hemostasis is impaired during CABG and coagulation abnormalities often result in clinically relevant organ dysfunctions, eventually increasing morbidity and mortality rates.
Results with an Anticoagulation Protocol in 99 SynCardia Total Artificial Heart Recipients
For 15 years, we employed a consistent anticoagulation protocol in 99 consecutive SynCardia Systems total artificial heart (TAH) recipients.
Management of Patients with Hematological Malignancies Undergoing Coronary Artery Bypass Grafting
We describe three cases with hematological malignancies namely chronic myelogenous leukemia, acute promyelocytic leukemia and chronic lymphocytic leukemia presenting for coronary artery bypass grafting (CABG).
Monitoring Incomplete Heparin Reversal and Heparin Rebound After Cardiac Surgery
To assess the incidence of incomplete heparin reversal and heparin rebound after cardiac surgery with cardiopulmonary bypass (CPB) and the ability of the activated coagulation time (ACT) and thromboelastography (TEG) to detect these phenomena.
Contribution of Endogenous Bradykinin to Fibrinolysis, Inflammation, and Blood Product Transfusion Following Cardiac Surgery: A Randomized Clinical Trial
This study tested the hypothesis that endogenous bradykinin contributes to the fibrinolytic and inflammatory response to CPB
Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery
We evaluated the role of platelet function testing in clopidogrel-treated patients undergoing CABG.
Monitoring Incomplete Heparin Reversal and Heparin Rebound After Cardiac Surgery
ACT is not able to detect residual heparin activity
Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery
We evaluated the role of platelet function testing in clopidogrel-treated patients undergoing CABG.